Seelos Therapeutics Inc. (NASDAQ:SEEL) trading with an addition of $0.09 to $2.45 on Thursday, an upside of 3.82 percent. An average of 2,603,885 shares of common stock have been traded in the last five days. There was a gain of $0.12 in the past week, and it reached a new high 27 times over the past 12 months. The last 20 days have seen an average of 6,294,021 shares traded, while the 50-day average volume stands at 3,547,625.
SEEL stock has increased by 26.20% in the last month. The company shares reached their 1-month lowest point of $1.83 on 09/20/21. With the stock rallying to its 52-week high on 04/27/21, shares of the company touched a low of $0.72 and a high of $6.60 in 52 weeks. It has reached a new high 18 times so far this year and achieved 49.37% or $0.86 in price. In spite of this, the price is down -62.88% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Seelos Therapeutics Inc. (SEEL) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.78 for the sector. In the last five years, Seelos Therapeutics Inc.’s PE ratio has ranged between 8.243 and 1.029. The stock’s beta is 2.82. Other valuation ratios to consider include the price-to-book (PB) ratio at 2.51.
The quick ratio of Seelos Therapeutics Inc. for the three months ended June 29 was 11.90, and the current ratio was 11.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $18.76 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Seelos Therapeutics Inc.’s return on assets was -96.90%, compared to -228.7% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$8.86 million in the quarter, while revenues of -$19.12 million were grew 57.9%. The analyst consensus anticipated Seelos Therapeutics Inc.’s latest quarter earnings to come in at -$0.12 per share, but it turned out to be -$0.1, a 16.70% surprise. For the quarter, EBITDA amounted to -$6.2 million. Shareholders own equity worth $102.31 million.
From a technical analysis perspective, let’s take a brief look at Seelos Therapeutics Inc. (SEEL) price momentum. RSI 9-day as of the close on 13 October was 62.64%, suggesting the stock is Neutral, with historical volatility in this time frame at 56.81%.
As of today, SEEL’s price is $2.31 +5.17% or $0.12 from its 5-day moving average. SEEL is currently trading +23.86% higher than its 20-day SMA and -24.22% lower than its 100-day SMA. However, the stock’s current price level is +15.64% above the SMA50 and +67.12% above the SMA200.
The stochastic %K and %D were 37.49% and 35.52%, respectively, and the average true range (ATR) was 0.17. With the 14-day stochastic at 44.88% and the average true range at 0.18, the RSI (14) stands at 59.04%. The stock has reached 0.05 on the 9-day MACD Oscillator while the 14-day reading was at 0.01.
ROTH Capital upgraded Seelos Therapeutics Inc. (NASDAQ: SEEL) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Seelos Therapeutics Inc. (SEEL) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SEEL, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is SEEL’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $14.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for Seelos Therapeutics Inc. (SEEL) stock is $9.50.